English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

B otulinum toxin type A (Botox; Allergan Inc, Irvine, California) injection for facial enhancement is the most common cosmetic procedure performed in the United States. Patient comfort and pain control is important for patient satisfaction and for patient retention after the cosmetic procedure. The use of preservativecontaining isotonic sodium chloride solution (normal saline), topical anesthesia, and cryoanalgesia prior to injection of botulinum toxin type A or B decreases patient discomfort, as does the use of 32-gauge rather than 30-gauge needles. Since intrafollicular orifice injection (IFOI) decreases the pain of local anesthesia, we extend the technique to the injection of botulinum toxin into the glabellar region. In the present study, we compared the IFOI technique with nonfollicular traditional injection (TI) with regard to patient pain perception.

Intrafollicular Orifice Injection Technique for Botulinum Toxin Type A